Yatharth Hospital & Trauma Care ServicesQ2 FY24

Yatharth Hospital & Trauma Care Services Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,109.55P/E: 56.1Market Cap: ₹10.7K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • Revenue grew 36% YoY to ₹3,258 million in H1 FY24, with 34% YoY growth in Q2.
  • Expect quarter-on-quarter top-line growth in coming quarters and years.
  • Focus on increasing capacity utilization across existing hospitals except Noida, which is running high.
  • Expansion plans to double bed capacity over 3-4 years via greenfield, brownfield, and acquisitions.
  • Oncology services and robotic surgeries to commence in Q4 FY24, expected to boost revenues.
  • International patient inflows from SAARC and CIS countries expected to grow significantly.
  • Organ transplant and medical tourism businesses expanding, anticipated to improve ARPOB and revenues.
  • New acquisitions (150-250 beds) planned before fiscal year-end to increase capacity and revenue.
  • Noida extension and Greater Noida hospitals poised for strong catchment growth aiding revenue increase.

See what Yatharth Hospital & Trauma Care Services management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The company is currently net debt-free as of September 2023, with a net cash position of ₹3,109 million, primarily from IPO proceeds.
  • For the planned expansion, including addition of approximately 1,400-1,450 beds over the next three years, the company has Capex plans of around ₹800 crore.
  • The company does not expect to require any long-term loan capital to fund these projects and is sufficiently funded for this expansion.
  • No specific mention of new equity fundraising beyond the recently completed IPO.
  • Focus remains on sustainable growth using existing funds without additional debt or equity raising at this point.

See what Yatharth Hospital & Trauma Care Services management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Planned Capex of around ₹800 crore over the next three years for adding approximately 1,400-1,450 beds.
  • Expansion includes both greenfield (new construction) and brownfield projects (expansion of existing facilities).
  • Capex may vary depending on the proportion of beds added through O&M (Operations & Management) model versus greenfield construction.
  • The company is sufficiently funded for this expansion, with no expected need for additional long-term loans.
  • Acquired adjacent land parcels at Greater Noida hospital and Noida Extension hospital to support organic expansion.
  • Expect first capacity increase through hospital acquisition (150-250 beds) to be completed by fiscal year-end.
  • Expansion aimed at boosting specialties like oncology, organ transplants, and international patient business.
  • Robotic surgery equipment will be commissioned soon as part of oncology service expansion.

Track Yatharth Hospital & Trauma Care Services — get its next earnings analysis in your feed

How does Yatharth Hospital & Trauma Care Services rank vs peers in Healthcare Services?

Pro feature
ThisYatharth Hospital & Trauma Care Services
Rev 2Mar 3

How does Yatharth Hospital & Trauma Care Services rank in Healthcare Services?

Compare Yatharth Hospital & Trauma Care Services against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →